Fosun Pharmaceutical announced that its holding subsidiary Zhaohui Pharmaceutical has received approval from the State Drug Administration to conduct clinical trials with ketoprofen patches and plans to conduct phase III clinical trials in China after conditions are met. This drug is intended to be used for analgesia and anti-inflammatory treatment of various diseases and symptoms. As of October 2025, the Group has invested a total of about 960,000 yuan in research and development of this drug. In 2024, the sales volume of ketoprofen preparations in China was about 91.16 million yuan. The drug still needs to be clinically studied and approved before it can be marketed. Research and development is at risk.

Fosun Pharmaceutical announced that its holding subsidiary Zhaohui Pharmaceutical has received approval from the State Drug Administration to conduct clinical trials with ketoprofen patches and plans to conduct phase III clinical trials in China after conditions are met. This drug is intended to be used for analgesia and anti-inflammatory treatment of various diseases and symptoms. As of October 2025, the Group has invested a total of about 960,000 yuan in research and development of this drug. In 2024, the sales volume of ketoprofen preparations in China was about 91.16 million yuan. The drug still needs to be clinically studied and approved before it can be marketed. Research and development is at risk.